Richard E. Gilbert

MD, FRCPC, FRACP, FACP, FASN, PhD

Scientist

Biography

Richard Gilbert is Professor of Medicine at the University of Toronto, Canada Research Chair in Diabetes Complications and Head of the Division of Endocrinology at St. Michael’s Hospital in Toronto.  Dr. Gilbert has published over 230 peer-reviewed manuscripts, has numerous patents, is frequently invited as a keynote speaker at major international conferences, and co-founded Fibrotech, a biotechnology company that has brought novel anti-fibrotic therapies from the bench to early phase human trials.  Following Fibrotech’s acquisition in 2014, Dr. Gilbert then founded another biotech company, Fibrocor Therapeutics, and is currently its Chief Scientific Officer designing and overseeing research projects that lead to the development of new therapies for the prevention and treatment of diseases of fibrosis such as cirrhotic liver disease, pulmonary fibrosis, chronic kidney disease and heart failure. In addition to his bench research, Dr. Gilbert is actively involved in teaching and knowledge translation with membership of Guidelines Committees for CHEP and Diabetes Canada on the management of hypertension, heart failure and chronic kidney disease in diabetes.

Recent Publications

  1. Sarak, B, Verma, S, David Mazer, C, Teoh, H, Quan, A, Gilbert, RE et al.. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovasc Diabetol. 2021;20 (1):200. doi: 10.1186/s12933-021-01390-8. PubMed PMID:34607574 PubMed Central PMC8491405.
  2. Hare, GMT, Zhang, Y, Chin, K, Thai, K, Jacobs, E, Cazorla-Bak, MP et al.. Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. Physiol Rep. 2021;9 (12):e14890. doi: 10.14814/phy2.14890. PubMed PMID:34184431 PubMed Central PMC8239445.
  3. Mason, T, Coelho-Filho, OR, Verma, S, Chowdhury, B, Zuo, F, Quan, A et al.. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. JACC Cardiovasc Imaging. 2021;14 (6):1164-1173. doi: 10.1016/j.jcmg.2020.10.017. PubMed PMID:33454272 .
  4. Veitch, MR, Thai, K, Zhang, Y, Desjardins, JF, Kabir, G, Connelly, KA et al.. Late intervention in the remnant kidney model attenuates proteinuria but not glomerular filtration rate decline. Nephrology (Carlton). 2021;26 (3):270-279. doi: 10.1111/nep.13828. PubMed PMID:33179827 .
  5. Chin, K, Cazorla-Bak, MP, Liu, E, Nghiem, L, Zhang, Y, Yu, J et al.. Renal microvascular oxygen tension during hyperoxia and acute hemodilution assessed by phosphorescence quenching and excitation with blue and red light. Can J Anaesth. 2021;68 (2):214-225. doi: 10.1007/s12630-020-01848-5. PubMed PMID:33174162 .
  6. Gilbert, RE, Caldwell, L, Misra, PS, Chan, K, Burns, KD, Wrana, JL et al.. Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. Can J Diabetes. 2021;45 (2):162-166.e1. doi: 10.1016/j.jcjd.2020.07.003. PubMed PMID:32917504 PubMed Central PMC7368650.
  7. Misra, PS, Szeto, SG, Krizova, A, Gilbert, RE, Yuen, DA. Renal histology in diabetic nephropathy predicts progression to end-stage kidney disease but not the rate of renal function decline. BMC Nephrol. 2020;21 (1):285. doi: 10.1186/s12882-020-01943-1. PubMed PMID:32682403 PubMed Central PMC7368674.
  8. Rabi, DM, McBrien, KA, Sapir-Pichhadze, R, Nakhla, M, Ahmed, SB, Dumanski, SM et al.. Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2020;36 (5):596-624. doi: 10.1016/j.cjca.2020.02.086. PubMed PMID:32389335 .
  9. Bami, K, Gandhi, S, Leong-Poi, H, Yan, AT, Ho, E, Zahrani, M et al.. Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. J Am Soc Echocardiogr. 2020;33 (5):644-646. doi: 10.1016/j.echo.2020.02.005. PubMed PMID:32199780 .
  10. Opingari, E, Verma, S, Connelly, KA, Mazer, CD, Teoh, H, Quan, A et al.. The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrol Dial Transplant. 2020;35 (5):895-897. doi: 10.1093/ndt/gfz294. PubMed PMID:32159783 .
Search PubMed

Affiliations & Other Activities

  • Staff Physician, Department of Medicine, Division of Endocrinology, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
X